Call Our
HELPLINE
1-800-4PD-INFO

National Parkinson Foundation's blog

Tips to Help Manage Anxiety

Date: 
Monday, May 22, 2017
Author: 
National Parkinson Foundation

Living with Parkinson’s can be stressful, triggering a cascade of worries. Anxiety is common among people with Parkinson’s and can take many forms: general anxiety, panic attacks, social phobia or attacks brought on by isolated instances, to name a few.

Center of Excellence Series: Toronto Western Hospital’s Parkinson’s Fellowship Program

Date: 
Thursday, May 11, 2017
Author: 
National Parkinson Foundation

There are approximately 3,000 movement disorder specialists in the world. While they are all neurologists, not all of them have experience treating Parkinson’s disease (PD). For every person with Parkinson’s to receive treatment from a specialist, each one of these doctors would have to treat more than 3,000 people with PD. Parkinson’s Foundation estimates that the average movement disorder specialist sees a total of 350 patients. That’s more than 8.9 million people with PD who are not being treated by a specialist.

What's Hot in PD?: Subcutaneous Apomorphine Infusions

Date: 
Wednesday, May 3, 2017
Author: 
Dr. Michael S. Okun

Should we consider subcutaneous apomorphine infusions for Parkinson’s disease patients who do not want deep brain stimulation or a dopamine pump? There is a growing interest among people with Parkinson’s disease (PD) and families for a “nonsurgical” alternative to deep brain stimulation (DBS) surgery or to Duopa pump therapy. The idea of brain surgery or a feeding tube have been cited as being undesirable for large numbers of PD patients.

History of Parkinson’s Disease

Date: 
Thursday, April 27, 2017
Author: 
National Parkinson Foundation

Parkinson’s disease (PD) has seen an elevation in recognition over the last few decades. Through the help of media, celebrities and events that promote PD awareness, Parkinson’s is far from an unknown disease. While we still have a long way to go to educate and make everyone aware of Parkinson’s and its impact, the history of this disease goes back to 1,000 B.C.

      

What's Hot in PD? Everything a Parkinson’s Patient Needs to Know about Safinamide (Xadago): Should You Switch?

Date: 
Monday, April 3, 2017
Author: 
Dr. Michael S. Okun

Safinamide (Xadago) was approved by the Food and Drug Administration (FDA) for treatment of Parkinson’s disease (PD) medication fluctuations. Safinamide is a pill that when absorbed in the bloodstream travels to the brain and affects dopaminergic and non-dopaminergic systems.

Pages